Skip to main content
. 2023 Aug 16;15(8):2149. doi: 10.3390/pharmaceutics15082149

Figure 8.

Figure 8

Effect of Br-MSCs and/or their derived EXOs on renal LC3-II mRNA and protein expression (A–H). (A) Relative expression of Beclin-1/Gapdh (% control), (B) photomicrographs of anti-LC3 immune-stained sections of the renal cortical structures in control group showed strong positive brown cytoplasmic immunostaining (arrow head) in the epithelial cells of the renal tubules (T) and glomerular endothelial cells (G), (C,D) photomicrographs of anti-LC3 immune-stained sections of the renal cortical structures in nephropathy and nephropathy + CM groups showed marked reduction in cytoplasmic immunoreactivity in the epithelial cells of the renal tubules (T) and glomerular cells (G), (E,F) photomicrographs of anti-LC3 immune-stained sections of the renal cortical structures in nephropathy + MSCs and nephropathy + EXOs groups showed marked increase in the immune reaction (arrow head) in the renal tubular cells (T) and the glomerular cells (G), (G) photomicrographs of anti-LC3 immune-stained sections of the renal cortical structures in nephropathy + MSCs + EXOs group showed strong immune reaction similar to that of control group (arrow head) in the epithelial cells of the renal tubules (T) and the glomerular cells (G), and (H) area % of LC3-II positive immunostaining. Values are the mean of (n) 6–8 rats per group ± S.E.M. ** p < 0.01, *** p < 0.001 **** p < 0.0001. (LC3 immunoperoxidase stain counterstained with H.; X400, Scale bar = 50 μm.)